Genomic and immunologic correlates of LAG-3 expression in cancer.

ABSTRACT: Immune checkpoint blockade leads to unprecedented responses in many cancers. Although currently available agents mostly target the PD-1 and CTLA-4 pathways, agents targeting the immune checkpoint protein LAG-3 are under active clinical development, and early clinical data show that LAG-3 expression is a biomarker of response to LAG-3 blockade. To determine which cancers may benefit most from LAG-3 blockade, we performed a pan-cancer analysis of The Cancer Genome Atlas dataset to identify genomic and immunologic correlates of LAG-3 expression. High mutation burden, and expression of exogenous virus (EBV, HPV) or endogenous retrovirus (ERV3-2), were associated with overexpression of LAG-3 in multiple cancers. Although CD8⁺ T-cell marker (CD8A) an

SUBMITTER: Panda A 

PROVIDER: S-EPMC7458666 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature